To The Moon

DocuSign shares fell 1% to $92.9 on June 6, 2025, with a steeper 14%–17% after-hours plunge following its Q1 FY2026 earnings release. While revenue grew 7% YoY to $710M and EPS improved to $0.16 (vs. $0.00 in Q1 2024), investor sentiment soured due to billings growth concerns and trimmed full-year guidance. Analyst Sentiment & Valuation Target Price: $92.77 (mean; +0.1% upside from current $92.9). Recommendations: 2 Buy, 17 Hold, 1 Underperform. Bull Case: Successful IAM adoption could re-rate shares to $124. Bear Case: Billings stagnation may push valuation toward $65. Conclusion: Hold for Strategic Turnaround While DocuSign’s billings miss and guidance cut justify near-term caution, its strong cash flow, leadership in e-signature, and IAM growth optionality suggest the selloff overst

DocuSign shares fell 1% to $92.9 on June 6, 2025, with a steeper 14%–17% after-hours plunge following its Q1 FY2026 earnings release. While revenue grew 7% YoY to $710M and EPS improved to $0.16 (vs. $0.00 in Q1 2024), investor sentiment soured due to billings growth concerns and trimmed full-year guidance. Analyst Sentiment & Valuation Target Price: $92.77 (mean; +0.1% upside from current $92.9). Recommendations: 2 Buy, 17 Hold, 1 Underperform. Bull Case: Successful IAM adoption could re-rate shares to $124. Bear Case: Billings stagnation may push valuation toward $65. Conclusion: Hold for Strategic Turnaround While DocuSign’s billings miss and guidance cut justify near-term caution, its strong cash flow, leadership in e-signature, and IAM growth optionality suggest the selloff overst